RAF1 and non-small cell lung carcinoma: Discovery of the oncogenic capacity of BRAF spurred the development of RAF inhibitors, with proven clinical benefit in BRAF aberrant melanoma, colorectal cancer, NSCLC, and papillary thyroid carcinoma (9–12).